Objective: Identifying a platelet count as abnormal (thrombocytopenia or thrombocytosis) can facilitate recognizing various disease states. However, the published reference ranges for platelet counts in neonates may be imprecise, as they were generated from relatively small sample sizes and compiled before modern platelet enumeration methods.
Introduction
An abnormally low concentration of platelets in the blood of a neonate (thrombocytopenia) can suggest the presence of any number of disease states. 1, 2 Likewise, an abnormally high concentration of platelets (thrombocytosis) can indicate the presence of a disorder. [3] [4] [5] [6] Therefore, measuring the concentration of platelets in the blood can be useful in neonatal medicine.
In adults, thrombocytopenia is generally defined by a platelet count below 150 000 ml À1 and thrombocytosis by a count above 450 000 ml À1 . 7 This same reference range has been used extensively for neonates, regardless of the gestational age or postnatal age. 8, 9 However, it is not clear if it is accurate. Previous studies reporting the reference range for platelet counts in neonates were limited by relatively small sample sizes [10] [11] [12] [13] [14] [15] and were generally single-institution reports using platelet enumeration equipment less accurate than is used currently. 16 In an attempt to bring more precision to the diagnosis of an abnormal platelet count in neonates, we compiled a very large sample size of platelet counts that had been obtained at various gestational and postnatal ages. To do this we used electronically archived laboratory and clinical data from neonates within Intermountain Healthcare, an 18-hospital system in the Western United States.
Methods
Data were collected as a deidentified limited data set from archived Intermountain Healthcare records. The information collected was limited to the data and information displayed in the figures of this report. Data were obtained for patients with a date of birth from 1 January 2001 through 30 September 2007 who had at least one platelet count obtained in the first 90 days of life at any Intermountain Healthcare Laboratory. Data from both inpatients and outpatients were included in the analysis. In an attempt to minimize any potential for selection bias all of the eligible records contained in the database were used for the analysis. Platelet values were measured using automated Beckman Coulter Hematology Analyzers (Beckman Coulter Inc., FL, USA). The gestational ages used in this study were those assigned by obstetrical dates, unless this was changed by the neonatal examination.
The program used for data collection was a modified subsystem of 'clinical workstation'. Clinical workstation is a Web-based electronic medical record application that stores demographic and clinical information, such as history, physical examination results, laboratory data, problem lists and discharge summaries. 3M Company (Minneapolis, MN, USA) approved the structure and definitions of all data points for use within the program. The data were collected from the electronic medical record, laboratory systems and case mix. Case mix is the billing, coding and financial data mart used by Intermountain Healthcare. Data were managed and accessed by authorized data analysts. The Intermountain Healthcare Institutional Review Board approved the study.
Descriptive statistics were calculated using Statit (Corvallis, OR, USA). Mean values and 5th and 95th percentiles were used to express the data. The 5th and 95th percentiles were calculated by looking at all the points and selecting a value at which only 5% of the total values were greater or less than that value. Mean platelet values were statistically analyzed using a student's t-test. Statistical significance was set as P<0.05. Linear regression analysis revealed that for each week increase in gestational age, there was a corresponding increase in mean platelet counts by 2089 m l À1 (P-value ¼ 0.000). Counts of those born before 35 weeks gestation were significantly lower than those that were of late-preterm and -term infants (P<0.05). In contrast to the increasing platelet counts with increasing gestational age, the MPV did not increase (Figure 1b) . In fact, as a group, those born before 31 weeks gestation had slightly higher MPVs than did those of late-preterm and -term infants (P<0.05).
Results

Between
The effect of advancing postnatal age on the platelet values of a composite of 47 291 infants born at 22 to 42 weeks gestation is shown in Figure 2 . Only the first recorded platelet count and the concurrent MPV of each patient was included in this analysis and data were utilized from inpatients and outpatients. Of the 47 291 patients, 56% were male, 76% were white and 29% were born prematurely (delivered at less than 37 weeks of gestation). During the first 9 weeks the platelet counts fit a sinusoidal pattern with peaks at 2 to 3 weeks and 6 to 7 weeks. The MPVs for this same group is shown in panel B. Mean values increased during the first two postnatal weeks, peaking at 9.5 fl, thereafter gradually decreasing with a plateau mean value of 8.5 fl. Figure 3 displays mean platelet counts with advancing postnatal age for prematurely born neonates. Counts are grouped according to weeks of gestation completed at birth. When groups are compared at equivalent postconceptional ages, platelet counts of those born at younger gestations were lower than those born at more mature gestations. Figure 4 provides details of the effect of advancing postnatal age on the platelet counts, displaying the 5th percentile, mean and 95th percentile values. Advancing postnatal age had little effect on the 5th percentile platelet counts, but had a significant effect on the 95th percentile counts. As those born at 25 to 26 weeks reached 32 to 33 weeks postconceptional age, the 95th percentile for platelet count extended as high as 550 000 m l À1 (Figure 4b ). The 95th percentile increased of above 500 000 m l À1 in the other groups as well (Figures 4c-f).
Discussion
Platelets have important roles in many biological processes, including thrombosis, inflammation and wound repair. 17 The presence of platelets in fetal blood by 12 weeks gestation suggests that these or other platelet functions are useful to the fetus. Relative inaccessibility of fetal blood sampling has limited study of fetal thrombopoiesis, but several investigators have reported platelet counts from fetal blood obtained by indicated cordocentieses. [18] [19] [20] [21] For instance, Van den Hof and Nicolaides 18 reported that fetal platelet counts increase linearly with gestation from a mean of 187 000 ml À1 at 15 weeks to 274 000 ml À1 at 40 weeks. In contrast, three studies reported no significant variation in platelet counts according to gestational age. [19] [20] [21] Conflicting reports have also been published regarding whether gestational age of newborn infants significantly affects platelet counts. Forty years ago Aballi et al. 22 reported that platelet counts of preterm infants were significantly lower than in full-term infants. In contrast, Sell and Corrigan 23 reported that the platelet counts of term and preterm infants are similar and do not vary significantly at different gestational ages. A recently published study reports that during the first week of life the mean platelet counts of neonates born at less than 35 weeks gestation were higher than the counts of more mature infants. 2 None of the previous studies reporting platelet counts in neonates had large sample sizes. The results of the present study, using samples from over 47 000 neonates, demonstrate that postnatal platelet counts do indeed increase with advancing gestational age. Panel A of Figure 1 illustrates that within the first three days of life, the initial platelet counts of neonates born between 22 and 35 weeks gestation were significantly lower than those of late-preterm and -term infants. Also, neonates of all gestational ages had a lower limit of expected platelet count (5th percentile) lower than the standard adult value of 150 000 ml À1 . In fact, the 5th percentile count was 104 200 ml
À1
for those p32 weeks gestation and 123 100 ml À1 for late-preterm and -term neonates.
Others have also questioned the validity of defining neonatal thrombocytopenia by a count below 150 000 ml
. For instance, Obladen et al. 24 reported that the 5th percentile platelet count for a cohort of 562 very low birth weight infants on day of life three was 75 000 ml À1 . Haque and Bahakim 10 reported the 5th percentile value on day of life one for 550 neonates delivered between 24 to 36 weeks gestation was approximately 100 000 ml À1 . Similar to our present report, several studies indicate that platelet counts increase during the neonatal period. 2, 22, [24] [25] [26] [27] Sasanakul et al. 25 noted a steady rise in the platelet counts of term infants during the first 7 to 14 postnatal days with subsequent counts remaining fairly constant over the next 2 weeks. Aballi et al. 22 evaluated platelet counts of premature infants whose birth weights ranged from 750 to 2250 g and observed a steady rise in counts during the first 24 days. Other studies have shown that the mean platelet counts of premature infants with birth weights <2500 g increase steadily during the first 10 to 14 days of life then remain constant over the remainder of the neonatal period. 26, 27 Obladen et al. 24 determined that the platelet counts of 562 very low birth weight infants increased steadily during the first 6 weeks of life, with the most significant increase noted during the first 2 weeks. Saxonhouse et al. 28 reported that reticulated platelet counts increase during the first 5 days following delivery. Our current findings corroborate and extend the work of those findings. We observed, using data from over 47 000 neonates, that during the first 9 weeks after birth platelet counts fit a sinusoidal pattern, with two peaks; one at 2 to 3 weeks and a second at 6 to 7 weeks ( Figure 2 ). Thrombopoietin (Tpo) is the primary regulator of megakaryopoiesis and platelet production. 29 It is well established that Tpo concentrations in non-thrombocytopenic preterm and term infants are significantly higher than in healthy adults. [30] [31] [32] Both preterm and term infants show similar Tpo concentrations during the first weeks of life; concentrations increase after birth with a peak on the 2nd day and then gradually decrease to levels seen in the cord blood by the end of the first month of life. 27, 32 Previous reports demonstrated that the platelet counts of neonatal rhesus monkeys began to increase 4 to 6 days after the administration of pegylated recombinant human megakaryocyte growth and development factor with counts peaking after approximately 2 weeks. 33 Collectively, these results suggest that the increase in platelet counts noted between the second and third postnatal week may be the result of a neonatal surge in Tpo and possibly other thrombopoietic factors. The cause of the second platelet count peak (Figure 2a) is not apparent. An increase in platelet counts is generally caused by an increase in platelet production. We are not aware of a condition where an increase in platelet counts is caused by a prolongation of platelet survival. Temporary elevations in platelet counts have been described in a variety of clinical settings including, infections (viral and bacterial), hypoxemia of either respiratory or cardiac origin, iron deficiency anemia and postoperatively 6 and these might be mediated by an increase in production of Tpo or other thrombopoietic factors. 34 Another possibility is that this second peak is a reactive thrombocytosis following the physiological nadir in hemoglobin concentration. 35 We recognize that an important pitfall in the present study is that all values were obtained because of a clinician's order, and thus these are not 'normal values'. Specifically, the clinical condition for which the platelet count was ordered likely resulted in a collection of platelet counts that differ from those of truly normal neonates. Thrombocytosis is defined as a platelet count above the normal limit for age. Therefore, both the diagnosis and the pathophysiologic significance of thrombocytosis is based on the knowledge of age-dependent normal platelet values. The results of the present study demonstrate that after the first postnatal week the upper limit of expected counts (95th percentile) is consistently greater than the standard adult value of 450 000 ml À1 , and in fact is as high as 750 000 ml À1 (Figure 2a ). Although the majority of patients in this study population were born at term and near-term we also noted that the upper limit of expected platelet counts (95th percentile) in preterm infants was frequently greater than 650 000 ml À1 during the postnatal period (Figures 3b-f ). We observed a correlation between the gestational age at birth and the time required postnatally before platelet counts begin to increase, and also the time for values to equal those of term infants (Figures 3 and 4) . The mean postnatal platelet counts of infants born between 29 and 34 weeks increased steadily over the first 2 to 3 weeks and then remained constant through a postconceptional age of 36 weeks at levels similar to those of late-preterm and -term infants (Figures 3 and 4d-f) . In contrast, postnatal platelet counts of those born between 22 and 27 weeks did not begin to increase until after they reached a corrected gestational age of approximately 29 weeks. As they reach a corrected gestational age of 36 weeks the mean platelet counts of the most immature group of infants remained below the mean levels measured in near-term and term infants. (Figures 3, 4a and b) . These results are similar to those reported by McPherson and Juul 2 , who characterized platelet counts over the first 4 weeks among infants born between 24 weeks gestation and term, noting that platelet counts increased over the first 4 weeks for all but the most preterm infants.
The postnatal 5th percentile values for platelet counts in infants born at less than 31 weeks gestation calls for comment (Figures  4a-d) . We contend it unlikely that a platelet count of 50 000 ml À1 is within the 'normal physiologic range' for these low birth weight patients. The birth of a preterm infant is frequently triggered by a variety of perinatal complications that are capable of influencing hematologic parameters as are many of the disease processes that afflict infants who are born prematurely. The 5th percentile platelet values, for these not uncommonly critically ill infants, are likely the pathologic consequence of any number of confounding factors.
Platelets are heterogeneous with respect to size, density, age, metabolism and function. [36] [37] [38] [39] [40] [41] [42] A literature developed several decades ago supports the idea that platelet heterogeneity is the result of platelet senescence, with large dense platelets, presumably those recently released from the bone marrow, becoming smaller and lighter as they age in the circulation. [36] [37] [38] [39] However, subsequent studies suggest that platelets do not change in size as they age in the circulation and that MPV is determined at or before the time of megakaryocyte fragmentation into platelets. 40 recently, the MPV has been the subject of significant research among adult patients with cardiovascular diseases, establishing that higher MPVs identify patients more likely to have poorer outcome after an acute vascular event. [43] [44] [45] It has been proposed in these patients that a larger MPV is an indicator of increased platelet activation. 46 The paucity of gestational age-based normative data has limited the clinical utility of MPVs in neonatal medicine. Patrick and Lazarchick 47 quantified the MPV of 143 healthy neonates (78 term and 65 preterm) and found they were significantly higher in term than in preterm infants. Likewise, Beverly et al. 48 reported that MPV values increase with advancing gestational age. In contrast, Arad et al. 15 found no difference in MPV between larger infants (greater than 2 kg) and smaller infants (less than 2 kg). Similarly, Kipper and Sieger 49 reported that the MPVs of 10 premature infants (26 to 34 weeks gestation) and 27 term infants were not significantly different. Our current study indicates that MPVs are rather constant from 22 to 42 weeks, with a slight but statistically significant decrease between the earlier vs later gestations (Figure 1b) . In addition, consistent with the findings of other investigators, 15 our current study demonstrates a significant rise in MPV over the first two postnatal weeks (Figure 2b ).
In conclusion, the long-held definitions of neonatal thrombocytopenia (<150 000 ml À1 ) and neonatal thrombocytosis (>450 000 ml À1 ) require revision. Depending on the pre-and postnatal age of the subject tested, normal platelet counts can fall below 150 000 and considerably above 450 000 yet be within the reference range (5th to 95th percentile). Using these new reference ranges, the number of neonates qualifying for the definitions of thrombocytopenia or thrombocytosis will be fewer than previous estimates. 
